NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Zelenirstat Antibody Drug Conjugate Data Presentation at World ADC 2025
TL;DR
Pacylex and Heidelberg Pharma's collaboration demonstrates zelenirstat's potential as a novel ADC payload, offering a competitive edge in cancer treatment with significantly enhanced potency.
Zelenirstat functions as an NMT inhibitor payload in ADCs, showing 20 to 1000-fold increased potency against cancer cell lines through targeted delivery mechanisms.
This innovative cancer therapy partnership advances targeted treatment options, potentially improving survival outcomes and quality of life for patients with difficult-to-treat cancers.
Pacylex transforms their oral cancer drug into powerful ADC payloads, achieving remarkable potency increases by combining novel mechanisms with cutting-edge antibody technology.
Found this article helpful?
Share it with your network and spread the knowledge!
The companies are presenting positive data showing zelenirstat works effectively as a payload in antibody drug conjugates (ADCs) for treating breast and prostate cancer, with significantly increased potency compared to oral zelenirstat alone.
Zelenirstat has a unique mechanism of action as an N-myristoyltransferase inhibitor that targets multiple cancer cell growth processes, and there's a need for new ADC payloads since very few have entered clinical practice.
The zelenirstat ADCs showed 20-fold to more than 1,000-fold higher potency against cancer cell lines compared to zelenirstat alone.
The data is being presented at the 16th Annual World ADC conference from November 3-6, 2025, in San Diego, California, with a specific poster presentation on November 4, 2025.
The ADCs were tested against multiple breast and prostate cancer cell lines using different targeting molecules and linkers.
Dr. Michael Weickert is the CEO of Pacylex Pharmaceuticals and can be contacted via email at michael.weickert@pacylex.com or phone at 650-218-1840. He will be available during the poster session and for one-on-one meetings.
Zelenirstat has completed a Phase 1 multiple ascending dose study in patients with relapsed/refractory lymphoma and refractory solid tumors (NCT04836195), showing acceptable safety and tolerability, and is currently in a clinical study for relapsed/refractory AML patients.
Pacylex has developed 28 NMT inhibitors with single-digit nM IC50s against human NMT1, and zelenirstat has demonstrated clinical safety and a novel mechanism of action that targets multiple cancer cell processes.
Clinical trial information is available on ClinicalTrials.gov under IDs NCT04836195 for the completed Phase 1 study and additional studies for AML patients.
Pacylex can be followed on Twitter @Pacylex (https://twitter.com/pacylex), LinkedIn (www.linkedin.com/company/pacylex-pharma), and Facebook (https://www.facebook.com/pacylex).
Curated from Reportable
